Press release
Peripheral Neuropathic Pain (PNP) Market to Reach USD 13.9 Billion by 2034
Peripheral Neuropathic Pain
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71919
PNP is difficult to treat, as many patients fail to respond to first-line therapies. Current management includes anticonvulsants, antidepressants, topical analgesics, opioids (limited use), and neuromodulation devices. With rising incidence of diabetes and cancer survivorship, along with innovation in gene therapies, regenerative medicine, and digital pain monitoring, the PNP market is entering a new growth phase.
Market Overview
• Market Size (2024): USD 7.6 billion
• Forecast (2034): USD 13.9 billion
• CAGR (2025-2034): 6.2%
Growth is fueled by rising diabetes prevalence, new drug approvals, and adoption of neuromodulation and digital pain management tools.
Key Highlights:
• Diabetes-related neuropathy affects ~50% of diabetic patients worldwide.
• FDA-approved therapies include pregabalin, duloxetine, lidocaine patches, and capsaicin 8% patch.
• Neuromodulation (spinal cord stimulation, peripheral nerve stimulation) expanding for refractory cases.
• Pipeline research includes sodium channel blockers, monoclonal antibodies, and gene therapy.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Anticonvulsants (Pregabalin, Gabapentin)
o Antidepressants (Duloxetine, Amitriptyline, Venlafaxine)
o Topical Analgesics (Lidocaine Patches, Capsaicin 8% Patch)
o Opioids (limited to refractory cases, safety concerns)
o Pipeline Agents (Nav1.7 sodium channel blockers, monoclonal antibodies, gene therapies)
• Non-Pharmacological Therapies
o Physical & Occupational Therapy
o Cognitive Behavioral Therapy (CBT) for pain coping
• Neuromodulation Devices
o Spinal Cord Stimulation (SCS)
o Peripheral Nerve Stimulation (PNS)
o Dorsal Root Ganglion (DRG) Stimulation
• Digital Pain Management Solutions
o AI-Powered Pain Tracking Apps
o Remote Monitoring Devices
o Virtual Reality (VR) Pain Distraction Tools
By Platform:
• Small Molecules (anticonvulsants, antidepressants)
• Biologics (monoclonal antibodies, regenerative therapies)
• Neuromodulation Devices
• Digital Therapeutics
By Technology:
• Next-Gen Sodium Channel Blockers
• Regenerative Medicine & Gene Therapy Platforms
• AI-Based Pain Monitoring
• Advanced Neuromodulation Systems
By End Use:
• Hospitals & Pain Clinics
• Neurology Centers
• Home Care Settings
• Research Institutes
By Application:
• Diabetic Peripheral Neuropathy (DPN)
• Postherpetic Neuralgia (PHN)
• Chemotherapy-Induced Neuropathy
• HIV-Associated Neuropathy
• Traumatic Nerve Injury
• Clinical Research
Segmentation Summary:
Pharmacological therapies dominate but face high non-response rates, making neuromodulation, biologics, and digital pain tools the fastest-growing categories.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71919/peripheral-neuropathic-pain-market
Regional Analysis
North America
• ~45% share in 2024.
• High diabetes prevalence and adoption of pregabalin/duloxetine.
• FDA approvals of advanced neuromodulation devices supporting growth.
Europe
• ~28% share.
• Germany, UK, and France leading in SCS and PNS adoption.
• EMA supporting sodium channel blocker and biologics pipelines.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.3%.
• High diabetes burden in India and China driving demand.
• Rising cancer survivorship fueling chemotherapy-induced neuropathy cases.
Middle East & Africa
• Growing prevalence of diabetes-related neuropathy.
• Limited access to advanced devices and biologics.
Latin America
• Brazil and Mexico leading adoption.
• Expanding access to generics and pain management centers.
Regional Summary:
North America and Europe dominate due to drug/device availability, while Asia-Pacific grows fastest due to rising diabetes prevalence and improving healthcare infrastructure.
Market Dynamics
Key Growth Drivers:
• Rising global prevalence of diabetes and cancer-related neuropathy.
• FDA/EMA approvals of new drugs and patches.
• Expanding adoption of spinal cord and peripheral nerve stimulators.
• Growth of digital health and remote pain monitoring tools.
Key Challenges:
• Limited efficacy and side effects of current drugs.
• High cost of neuromodulation devices.
• Underdiagnosis in low-resource regions.
• Long-term opioid safety concerns.
Latest Trends:
• Nav1.7 sodium channel blockers advancing in trials.
• Monoclonal antibodies targeting neuropathic pain pathways.
• Gene therapies and regenerative approaches under investigation.
• AI-based apps and VR platforms for personalized pain care.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71919
Competitor Analysis
Major Players in the Market:
• Pfizer Inc. (Pregabalin - Lyrica)
• Eli Lilly and Company (Duloxetine - Cymbalta)
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Johnson & Johnson (SCS devices via Nevro, Boston Scientific partnership)
• Medtronic plc (Spinal Cord Stimulation Systems)
• Abbott Laboratories (Neuromodulation Devices)
• Grunenthal GmbH (Capsaicin Patch - Qutenza)
• Daiichi Sankyo Co., Ltd.
• Vertex Pharmaceuticals (sodium channel blocker pipeline)
Competitive Summary:
Pfizer and Eli Lilly dominate pharmacological therapies. Medtronic, Abbott, and J&J lead neuromodulation devices. Grunenthal specializes in topical pain patches, while Vertex drives sodium channel blocker innovation. Competition focuses on pipeline biologics, regenerative medicine, and advanced pain devices.
Conclusion
The Peripheral Neuropathic Pain (PNP) Market, valued at USD 7.6 billion in 2024, is projected to reach USD 13.9 billion by 2034, growing at a CAGR of 6.2%. Rising diabetes prevalence, neuromodulation adoption, and pipeline innovations will continue to shape this market.
Key Takeaways:
• Pregabalin, duloxetine, and topical patches dominate today's market.
• North America and Europe lead, while Asia-Pacific grows fastest.
• Neuromodulation and sodium channel blockers are high-growth categories.
• AI-driven pain management and gene therapies hold long-term potential.
The next decade will transform PNP management from limited symptomatic relief to integrated pharmacological, device-based, and digital pain solutions, creating strong opportunities for pharma, medtech, and digital health innovators.
This report is also available in the following languages : Japanese (末梢神経障害性疼痛市場), Korean (말초 신경병증성 통증 시장), Chinese (周围神经性疼痛市场), French (Marché de la douleur neuropathique périphérique), German (Markt für periphere neuropathische Schmerzen), and Italian (Mercato del dolore neuropatico periferico), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71919/peripheral-neuropathic-pain-market#request-a-sample
Our More Reports:
Medical Isotope Production Market
https://exactitudeconsultancy.com/reports/72374/medical-isotope-production-market
Bioanalytical Testing Services Market
https://exactitudeconsultancy.com/reports/72373/bioanalytical-testing-services-market
Cartilage Repair Market
https://exactitudeconsultancy.com/reports/72372/cartilage-repair-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peripheral Neuropathic Pain (PNP) Market to Reach USD 13.9 Billion by 2034 here
News-ID: 4179640 • Views: …
More Releases from Exactitude Consultancy
Clinically Isolated Syndrome (CIS) Market reaching approximately USD 2.5 billion …
Clinically Isolated Syndrome (CIS) is a neurological condition that typically serves as the first episode of multiple sclerosis (MS), characterized by a single episode of neurological symptoms caused by inflammation or demyelination of the central nervous system. It is considered a precursor to MS, with many individuals who experience CIS eventually progressing to a diagnosis of relapsing-remitting MS (RRMS).
CIS often presents with symptoms like vision impairment, muscle weakness, and coordination…
Diabetic Peripheral Neuropathy (DPN) Market Emerging Trends and Growth Prospects …
Introduction
Diabetic peripheral neuropathy (DPN) is one of the most common and serious complications of diabetes mellitus, affecting millions of people globally. It occurs when prolonged high blood sugar levels cause nerve damage, particularly in the hands, feet, and legs. Patients with DPN often experience pain, tingling, numbness, and balance issues, which can lead to foot ulcers, infections, and even amputations if untreated.
With diabetes prevalence rising at alarming rates, especially in…
Dementia Market Projected to Reach USD 30.2 Billion by 2034
Dementia is a broad category of cognitive impairments, including memory loss, language difficulties, and poor judgment, often leading to a severe decline in daily functioning. Alzheimer's disease is the most common cause of dementia, but other forms, such as vascular dementia, Lewy body dementia, and frontotemporal dementia, also contribute to the global burden. As the global population ages, the prevalence of dementia is rising, with the number of people affected…
Cognitive Impairment Associated with Schizophrenia (CIAS) Market Detailed Indust …
Introduction
Schizophrenia is a chronic psychiatric disorder affecting approximately 1% of the global population, often characterized by hallucinations, delusions, and social withdrawal. However, beyond these hallmark symptoms, cognitive impairment associated with schizophrenia (CIAS) remains one of the most debilitating aspects of the disease. CIAS manifests as deficits in memory, attention, problem-solving, and executive function, severely limiting patients' ability to live independently, pursue employment, and maintain social relationships.
While traditional antipsychotics effectively manage…
More Releases for Pain
Enhanced Pain Relief Solutions at Advanced Pain Care
Image: https://www.globalnewslines.com/uploads/2025/03/3f3b6259bfdec02e5dcb7b9d0c838855.jpg
Advanced Pain Care is helping people who suffer from chronic pain with sophisticated, evidence-based treatments. The clinic is particularly focused on non-surgical care that improves the quality of life. With a team of highly qualified pain experts, they work with patients who have back pain, joint pain, and nerve pain.
Personalized Treatment for Every Pain Disorder
Advanced Pain Care offers treatments depending on the cause of pain. Anyone experiencing arthritis, migraine,…
Pain Finisher | Advanced Pain Relief Device
Pain Finisher is an instant pain relief device that is effective on all pains including back pain and knee pain. It is based on the TENS theory of pain management which is easy to use and safe.
By using Pain Finisher, a modern drug-free and non-invasive pain-relieving treatment method, one can get rid of the common pain creams, gels, and risky treatment methods.
So, have a pain-free life with easy-to-use pain relief…
Neuropathic Pain Market: Innovative Therapies Reshaping Chronic Pain Management
In recent years, the global Neuropathic Pain Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Neuropathic Pain Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including…
Visceral Pain Market Analysis 2024: Addressing Pain Management Challenges
The Business Research Company has released its latest global market reports, covering insights for 2024 and offering projections up to 2033.
The Business Research Company presents an extensive market research report on the Visceral Pain Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.
Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities,…
Global Post-Operative Pain Management Market: Pain Relief Goes Worldwide
Introduction:
The Global Post-Operative Pain Management Market is growing at a rapid pace. This market involves the management of pain after surgical procedures. The market has witnessed significant growth in recent years, owing to the increasing number of surgeries and the rising prevalence of chronic diseases. Pain management is an essential aspect of healthcare, as uncontrolled pain can lead to prolonged hospital stays, delayed recovery, and poor patient outcomes.
In this article,…
Post-Operative Pain Management Market By Type, By Application(Cancer Pain, Arthr …
Global Post-Operative Pain Management Market- Description
Post-operative pain management is predominantly referred to as the use of a wide array of therapies or drugs to reduce muscle and tissue spasm in patients who have recently undergone a surgical procedure. It is evident that all type of surgeries, be it major or minor cause postoperative pain in patients which in turn increases their hospital stays while burdening them with psychological and physical…
